Tirzepatide Linked to 32% Lower Risk of Major Cardiovascular Events
Recent findings published in Emjreviews indicate that tirzepatide is associated with a 32% lower risk of major adverse cardiovascular events compared to alternative treatments. Tirzepatide functions as a dual incretin agonist of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 receptors. Tirzepatide Linked to Lower Risk of Major Cardiovascular Events According to research covering 52,971 adults … Read more